Lee Danner & Bass Inc Biomarin Pharmaceutical Inc Transaction History
Lee Danner & Bass Inc
- $1.24 Billion
- Q4 2024
A detailed history of Lee Danner & Bass Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Lee Danner & Bass Inc holds 150 shares of BMRN stock, worth $10,237. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$10,237% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
626Shares Held
183MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.55 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.32 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.24 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$1.01 Billion0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$887 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.7B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...